Cubist Systematic Strategies’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Cubist Systematic Strategies’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-8,225	Closed	-$472K	–	2614
2019 Q4	$472K	Buy	8,225 +5,098	+163%	+$252K	0.01%	1582
2019 Q3	$112K	Buy	+3,127	New	+$122K	﹤0.01%	1912
2019 Q1	–	Sell	-2,180	Closed	-$30K	–	2496
2018 Q4	$30K	Buy	2,180 +2,098	+2,559%	+$26.5K	﹤0.01%	1924
2018 Q3	$1K	Sell	82 -1,583	-95%	-$26K	﹤0.01%	1852
2018 Q2	$34K	Buy	+1,665	New	+$34.9K	﹤0.01%	1680

Other funds holding EIDX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Cubist Systematic Strategies's EIDX Position: Q1 2020 in Review

Cubist Systematic Strategies sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2020, closing a stake of 8,225 shares — an estimated $472K sold.

Cubist Systematic Strategies first reported a position in EIDX in Q2 2018 and held it in 5 quarters. The position peaked at $472K in Q4 2019. 89 funds tracked by Wall St. Rank hold EIDX as of Q1 2020.

Cubist Systematic Strategies reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Cubist Systematic Strategies sold 8,225 Eidos Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $472K.
Cubist Systematic Strategies first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
Cubist Systematic Strategies's Eidos Therapeutics, Inc. Common Stock position peaked at $472K in Q4 2019.
89 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Cubist Systematic Strategies's 13F filing for Q1 2020, filed 15 May 2020.